"Participants will have a complete physical, blood work taken, keep symptom diaries,
complete questionnaires and continue with follow-up for 4 months. Cost of medication,
office visits, and blood work are paid by the study. This research has been approved
by the Institutional Review Board, under FDA regulations, at Penn State's College
Based on the anecdotal reports from patients with Crohn's disease from
past years, as well as the very positive outcomes of Professor Smith's initial, small,
open-label trial of LDN in Crohn's disease, the results of this Phase II trial should
confirm the potency and safety of LDN in the treatment of autoimmune disease.
sooner the trial is able to enroll its requisite number of people with Crohn's disease,
the sooner the trial will be completed and results published.
This, in turn, should
interest other researchers in a host of possible clinical trials for the many uses
of LDN, as well as help open the door to FDA approval.
If you know of people who have
Crohn's disease and could participate in the Penn State trial, please refer them
as soon as possible to coordinating nurse Sandra Bingaman, at 717-531-8108.
you for taking action in this important matter.